Filter
420
Text search:
Booster
Featured
36
87
Language
Document type
182
99
54
24
18
18
8
7
4
2
2
2
Countries / Regions
27
20
11
11
8
8
7
7
7
7
6
6
6
6
5
5
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
150
62
23
19
10
4
2
Toolboxes
87
23
18
17
17
13
13
12
10
9
8
5
5
5
5
4
4
3
2
2
2
1
September 2021
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel
Memorandum: Recommendation of interval for the application of the booster dose of COVID-19 vaccines
How much protection does the current batch of COVID-19 vaccines provide us? Would you need a booster shot for new variants? What does science and evidence tell us about mass gatherings and the spread of COVID-19?
WHO’s Chief Scientist Dr Soumya
...
Neonatal tetanus (NT), a severe newborn illness from the toxigenic strains of Clostridium tetani, persists in middle- and low-income countries due to non-sterile childbirth practices. Unlike smallpox and polio, tetanus cannot be eradicated: Clostridium tetani spores exist in the environment, and ani
...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition
...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so
...
Additional dose of the primary vaccination against COVID-19: Technical Guidelines
Ethnic disparities in COVID-19 persist, with increased rates of infection, severe disease, and death among people from minority ethnic groups. COVID-19 vaccination rates also remain lowest in these communities compared with white people in the UK. Among people older than 18 years, the proportion who
...
Accessed 7 July 2015
Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc
...
